Detection of tumour progression in the follow-up of irradiated low-grade astrocytomas: Comparison of 3-[123I]iodo-α-methyl-L-tyrosine and 99mTc-MIBI SPET

European Journal of Nuclear Medicine

Volumn 29, Issue 11, 2002, Pages 1445-1461

  Henze, Marcus ^a,b   Mohammed, Ashour ^a,b   Schlemmer, Heinz ^a,b   Herfarth, Klaus K ^a,b   Mier, Walter ^a,b   Eisenhut, Michael ^a,b   Debus, Jürgen ^a,b   Haberkorn, Uwe ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

123I IMT; 99mTc MIBI; Low grade astrocytoma; Radiotherapy

Indexed keywords

3 IODOMETIROSINE I 123; GADOLINIUM PENTETATE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 3 IODO ALPHA METHYLTYROSINE; 3-IODO-ALPHA-METHYLTYROSINE; DIAGNOSTIC AGENT; METIROSINE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CALCULATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; FOLLOW UP; HEMISPHERE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL SIGNIFICANCE; BRAIN TUMOR; CANCER INVASION; CANCER STAGING; METHODOLOGY; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY; SCINTISCANNING; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ASTROCYTOMA; BRAIN NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHYLTYROSINES; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M SESTAMIBI; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 1842867556     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-0896-0     Document Type: Article

References (51)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer Statistics. CA Cancer J Clin 1999; 49:8-31.
2. Herfarth KK, Gutwein S, Debus J. Postoperative radiotherapy of astrocytomas. Semin Surg Oncol 2001; 20:13-23.
3. Vick NA, Coroc IS, Eller TW. Reoperation for malignant astrocytoma. Neurology 1989; 39:430-432.
4. Li A, Shea WM, Wyn W. Radiosurgery as a part of the initial management of patients with malignant glioma. J Clin Oncol 1992; 10:1379-1385.
5. Forsyth PA, Kelly PJ, Cascino TL, Scheithauer BW, Shaw EG, Dinapoli RP, Atkinson EJ. Radiation necrosis or glioma recurrence: Is computer-assisted stereotactic biopsy useful? J Neurosurg 1995; 82:436-444.
6. Byrne TN. Imaging of gliomas. Semin Oncol 1994; 21:162-171.
7. Leeds NE, Jackson EF. Current imaging techniques for the evaluation of brain neoplasms. Curr Opin Oncol 1994; 6: 254-261.
8. Davis WK, Boyko OB, Hoffman JM et al. 18-F-FDG PET correlation of gadolinium-enhanced MR imaging of central nervous system neoplasia. AJNR Am J Neuroradiol 1993; 14:515-523.
9. 18F]Fluordeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology 1982; 144:885-889.
10. Glantz MJ, Hoffman JM, Coleman RE. The role of F18 FDG PET imaging in predicting early recurrence of primary brain tumors. Ann Neurol 1991; 29:347-355.
11. Di Chiro G, Oldfield E, Wright DC, De Michele D, Katz DA, Patronas NJ, Doppman JL, Larson SM, Ito M, Kufta CV. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Radiol 1988; 150:189-197.
12. Ishikawa M, Kikuchi H, Miyatake S, et al. Glucose consumption in recurrent gliomas. Neurosurgery 1993; 33:28-33.
13. 18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: A comparative study with stereotactic biopsy. Eur J Nucl Med 1999; 26:144-151.
14. Kubota R, Kubota K, Yamada S, et al. Methionine uptake by tumor tissue: A microautoradiographic comparison with FDG. J Nucl Med 1995; 36:484-492.
15. Langen KJ, Roosen N, Coenen H, et al. Brain and brain tumor uptake of L-3-[123-I] iodo-methyl tyrosine: Competition with naturalL-amino acids. J Nucl Med 1991; 32:1225-1228.
16. 125I]iodo-alpha-methyl-tyrosine SPECT in non-small cell lung cancer: Preliminary observations. J Nucl Med 2001; 42:579-585.
17. Kuwert T, Woesler B, Morgenroth C, et al. Diagnosis of recurrent glioma with SPECT and iodine-123-alpha-methyl tyrosine. J Nucl Med 1998; 39:23-27.
18. Schlemmer HP, Bachert P, Herfarth KK, Zuna I, Debus J, van Kaick G. Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy. AJNR Am J Neuroradiol 2001; 22:1316-1324.
19. 1H-MRSI. NMR Biomed 1999; 12:123-138.
20. Graves EE, Nelson SJ, Vigneron DB, et al. Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. AJNR Am J Neuroradiol 2001; 22:613-624.
21. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci 1978; 25:638-643.
22. Bubeck B, Eisenhut M, Heimke U, zum Winkel K. Melanoma affine radiopharmaceuticals. I. A comparative study of 131I-labelled quinoline and tyrosine derivatives. Eur J Nucl Med 1981; 6:227-233.
23. 124IMT and first clinical results. J Nucl Med 1990; 31:281-286.
24. 11C]-L-methionine uptake in cerebral gliomas: A comparative study using SPECT and PET. J Nucl Med 1997; 38:517-522.
25. 123I-labelled compounds in clinical practice. Eur J Nucl Med 1999; 26:655-658.
26. Andrews RJ. Transhemispheric diaschisis: a review and comment. Stroke 1991; 22:943-949.
27. Soler C, Beauchesne P, Maatougui K, Schmitt T, Barral FG, Michel D, Dubois F, Brunon J. Technetium-99m sestamibi brain single-photon emission tomography for detection of recurrent gliomas after radiation therapy. Eur J Nucl Med 1998; 25:1649-1657.
28. Maffioli L, Gasparini M, Chiti A, et al. Clinical role of technetium-99m sestamibi single-photon emission tomography in evaluating pretreated patients with brain tumours. Eur J Nucl Med 1996; 23:308-311.
29. Lamy-Lhullier C, Dubois F, Blond S et al. Importance of cerebral tomoscintigraphy using Tc-labelled sestamibi in the differential diagnosis of recurrent tumor vs. radiation necrosis in subtentorial glial tumors in the adult. Neurochirurgie 1999; 45:110-117.
30. Baillet G. Albuquerque L, Chen Q, Poisson M, Delattre JY. Evaluation of single-photon emission tomography imaging of supratentorial brain gliomas with technetium-99m-sestamibi. Eur J Nucl Med 1994; 21:1061-1066.
31. 99mTc-sestamibi. Nucl Med Commun 1995; 16:258-264.
32. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2methoxy isobutyl isonitrile) technetium (I) in cultured chick myocardial cells: Mitochondrial and plasma membrane potential dependence. Circulation 1990; 82:1826-1838.
33. 99mTc-sestamibi in high-grade malignant brain tumors reflect blood-brain barrier damage only? Neuroimage 2000; 12:109-111.
34. McCormack BM, Miller DC, Budzilovic GN, Voorhees GJ, Ransohoff J. Treatment and survival of low-grade astrocytoma in adults: 1977 - 1988. Neurosurgery 1992; 31:636-642.
35. Macapinlac A, Scott A, Cluser C, et al. Comparison of Tl-201 and Tc-99m MIBI with MRI in the evaluation of recurrent brain tumors. J Nucl Med 1992; 33:867.
36. Piwnica-Worms D, Chiu ML, Budding M, et al. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993; 53:977-984.
37. Taki J, Sumiya H, Asada N, et al. Assessment of P-glycoprotein in patients with malignant bone and soft tissue tumors using technetium-99m-MIBI scintigraphy. J Nucl Med 1998; 39:1179-1184.
38. Leitha T, Glaser G, Lang S. Is early sestamibi imaging in head and neck cancer affected by MDR status, p53 expression or cell proliferation? Nucl Med Biol 1998; 25:593-541.
39. Kawai K, Fujibayashi Y, Saji H, et al. A strategy for the study of cerebral amino acid transport using iodine-123-labelled amino acid radiopharmaceutical: 3-iodo-alpha-methyl-L-tyrosine. J Nucl Med 1991; 32:819-824.
40. 124IMT and first clinical results. J Nucl Med 1990; 31:281-286.
41. Kuwert T, Morgenroth C, Woesler B, et al. Uptake of iodine-123-alpha-methyl tyrosine by gliomas and non-neoplastic brain lesions. Eur J Nucl Med 1996; 23:1345-1353.
42. 18F-deoxyglucose. Eur J Nucl Med 1997; 24:428-434.
43. Weber W, Bartenstein P, Gross MW, et al. Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. J Nucl Med 1997; 38:802-808.
44. 123I-iodo-methyltyrosine uptake in brain tumor recurrences. Nuklearmedizin 1995; 34:71-75.
45. 11C]methionine uptake in brain abscess: A PET study. J Comput Assist Tomogr 1993; 17:660-661.
46. 201Tl-chloride on SPECT. Neuroradiology 1998; 40:435-438.
47. Wunderlich G, Schmidt D, Langen KJ, et al. Evaluation of chemotherapy in gliomas by I-123-methyltyrosine SPECT: first results. Eur J Nucl Med 1995; 22:796.
48. Otto L, Dannenberg P, Feyer P, et al. Iodine-123-methyl-tyrosine uptake of brain tumors - Influence of radiotherapy. Eur J Nucl Med 1995; 22:796.
49. Goldman S. Regional glucose metabolism and histopathology of gliomas. A study based on PET-guided stereotactic biopsy. Cancer 1996; 78:1098-1106.
50. Tatter SB, Wilson CB, Harsh GR. Neuroepithelial tumors of the adult brain. Neurological surgery, 4th edn, vol 4. Philadelphia: Saunders; 1996:2612-2684.
51. DiChiro G, Fulham MJ. Virchow's shackles: Can PET-FDG challenge tumor histology? AJNR 1993; 14:524-527.